Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Histone H2BK120 Ubiquitination Stabilizes DOT1L on Nucleosomes

DOI: 10.1158/2159-8290.CD-RW2019-060 Published June 2019
  • Article
  • Info & Metrics
Loading
  • Major Finding: H2BK120Ub stabilizes nucleosome-bound DOT1L, thus increasing its histone methyltransferase activity.

  • Concept: Ubiquitin binding stabilizes the conformation of DOT1L on the nucleosome, resulting in increased catalysis.

  • Impact: Structures of nucleosome-bound DOT1L may provide a framework for improved DOT1L inhibitor design.

Misregulation of DOT1L, a non–SET domain histone methyltransferase that catalyzes methylation of histone H3K79, is observed in numerous cancers—especially MLL-rearranged leukemias—and DOT1L inhibition has therapeutic promise in these cancers. Although it is observed that DOT1L's H3K79 methylation activity is stimulated by the presence of the H2BK120Ub modification, there is no detailed mechanistic information available regarding the cross-talk between these modifications. Valencia-Sánchez, De Ioannes, Wang, and colleagues report cryo-EM structures of human DOT1L bound to both unmodified and H2BK120 ubiquitinated nucleosome substrates. Notably, their structures captured DOT1L in a “post-catalysis” state on H2BK120Ub nucleosomesH3K79me1 and H3K79me2 could be detected by mass spectrometry in their samples, and SAH was present. DOT1L covers a large interaction surface, making direct contact with histone H4, the acidic patch residues of histones H2A and H2B, and DNA. The structure also clearly identified the regions responsible for direct contact with ubiquitin, with the most prominent interface occurring between the hydrophobic face of helix αK and the hydrophobic patch on ubiquitin. To understand the role of H2BK120Ub interactions in stimulation of DOT1L, they performed histone methyltransferase assays using various interface point mutants in DOT1L. Although these mutants could bind nucleosomes equally well as unmodified DOT1L, they showed impaired stimulation by H2BK120Ub, resulting in a reduction of H3K79me2 and loss of H3K79me3. This suggests that H2BK120Ub does not stimulate DOT1L by increasing its binding affinity and led the authors to hypothesize that H2B ubiquitination stimulates DOT1L activity by optimizing its position for catalysis. They compared the structures of DOT1L bound to unmodified and H2B-ubiquitinated nucleosomes and observed that although interactions with the acidic patch were still visible, DOT1L generally appeared much more mobile in the presence of unmodified H2B. This suggested that H2BK120Ub stimulates DOT1L catalysis by reducing its sampling space on the nucleosome by conformational restriction. Collectively, this work provides a framework for future studies of histone modification cross-talk and for the development of improved DOT1L inhibitors.

Valencia-Sánchez MI, De Ioannes P, Wang M, Vasilyev N, Chen R, Nudler E, et al. Structural basis of Dot1L stimulation by histone H2B lysine 120 ubiquitination. Mol Cell 2019 Apr 8 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

  • ©2019 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 9 (6)
June 2019
Volume 9, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Histone H2BK120 Ubiquitination Stabilizes DOT1L on Nucleosomes
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Histone H2BK120 Ubiquitination Stabilizes DOT1L on Nucleosomes
Cancer Discov June 1 2019 (9) (6) OF9; DOI: 10.1158/2159-8290.CD-RW2019-060

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Histone H2BK120 Ubiquitination Stabilizes DOT1L on Nucleosomes
Cancer Discov June 1 2019 (9) (6) OF9; DOI: 10.1158/2159-8290.CD-RW2019-060
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • In Vivo CRISPR Screen Identifies FLI1 as Regulator of Effector T Cells
  • Trial Supports Combination Treatment and New Target for Multiple Myeloma
  • Mitochondrial DNA Damage Triggers an IFN-Mediated Immune Response
Show more Research Watch

Epigenetics

  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • H1 Loss Increases Accessibility of Stemness Genes to Drive Lymphoma
Show more Epigenetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement